The researchers who resurrected Inrebic are testing a new bone marrow cancer drug in spacenews2023-10-06T15:24:19+00:00October 6th, 2023|Endpoints News|
Regeneron pays $100M milestone to Alnylam; NIH awards Clene $45M; Biohaven raises $258Mnews2023-10-06T14:52:29+00:00October 6th, 2023|Endpoints News|
Mirati reemerges as potential buyout target with rival Amgen under the microscopenews2023-10-06T14:44:02+00:00October 6th, 2023|Endpoints News|
Amgen closes $28B Horizon acquisition a month after FTC battle endednews2023-10-06T12:34:06+00:00October 6th, 2023|Endpoints News|
Abcam details negotiations behind $5.7B Danaher acquisition, takeover attempts by founder and former CEOnews2023-10-06T11:30:13+00:00October 6th, 2023|Endpoints News|
Pharma Proteomics Project uncovers treasure trove of new leads on drug targets and biomarkersnews2023-10-06T10:56:34+00:00October 6th, 2023|Endpoints News|
Apellis’ Syfovre on the comeback trail from vasculitis worries after $74M in initial Q3 salesnews2023-10-06T10:47:22+00:00October 6th, 2023|Endpoints News|
Dave Lennon’s CEO adventure goes from preclinical to commercial; GSK vet embarks on new Odyssey with Gary Glicknews2023-10-06T10:00:21+00:00October 6th, 2023|Endpoints News|
FDA’s oncology adcomm votes against Amgen’s confirmatory data for Lumakras in certain types of NSCLCnews2023-10-05T19:29:53+00:00October 5th, 2023|Endpoints News|
Atsena prioritizes retinal gene therapy pipeline, trims staff as existing investors refuel the biotech news2023-10-05T19:18:33+00:00October 5th, 2023|Endpoints News|
